Pulmonary arterial hypertension (PAH) is a condition in which the blood pressure in the pulmonary arteries is abnormally high. The pulmonary arteries are the blood vessels that carry blood from the heart to the lungs. In PAH, the walls of the pulmonary arteries become thickened and narrowed, which makes it difficult for blood to flow through them. This can cause symptoms such as shortness of breath, fatigue, and chest pain. PAH can be caused by a variety of conditions, including heart disease, lung disease, and certain medications. It is a progressive condition, meaning it typically gets worse over time. There is no cure for PAH, but treatments are available to help manage the symptoms and slow the progression of the disease.
Download Sample of Report : https://www.globalinsightservices.com/request-sample/GIS21396
Key Trends
Pulmonary arterial hypertension (PAH) is a chronic, progressive, and often fatal disease characterized by high blood pressure in the arteries of the lungs. There is no cure for PAH, and treatments are limited. However, there have been significant advances in the diagnosis and treatment of PAH in recent years.
The most important trend in PAH technology is the development of new and improved treatments. While there is no cure for PAH, treatments can improve symptoms and quality of life, and they may also slow the progression of the disease. In the past, treatments for PAH were limited to drugs that dilated blood vessels or improved blood flow through the lungs. These treatments are still important, but they have been joined by a new generation of drugs that target the underlying causes of PAH. These drugs, known as PAH-specific therapies, include drugs that block the formation of blood clots, improve the function of the heart, and reduce inflammation.
Key Drivers
Pulmonary arterial hypertension (PAH) is a rare and progressive condition characterized by high blood pressure in the arteries of the lungs. The condition can lead to heart failure and death. There are no cure for PAH, but treatments are available to improve symptoms and slow the progression of the disease.
The key drivers of the PAH market are the increasing prevalence of the disease, the availability of effective treatments, and the growing awareness of the condition. The prevalence of PAH is thought to be increasing due to the aging population and the increased use of diagnostic tools such as echocardiography. The availability of effective treatments, such as prostacyclin therapy, has also contributed to the growth of the PAH market. The growing awareness of the condition, through campaigns such as the Pulmonary Hypertension Association’s “PH Awareness Week”, has also helped to increase the market for PAH treatments.
Buy Now : https://www.globalinsightservices.com/checkout/single_user/GIS21396
Market Segments
The Pulmonary Arterial Hypertension Market is segmented based on the drug type, sales channel, and region. Under the drug type segment, the market is classified into endothelin receptor antagonists ERAs, prostacyclin & prostacyclin analogs, sGC stimulators, and PDE-5 dipsticks. Based on sales channel, market is studied across hospital pharmacy, retail pharmacy, and online pharmacy. Region-wise, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.
Key Players
The Pulmonary Arterial Hypertension Market report includes players such as United Therapeutic Corporation, Eli Lilly and Company, Actelion Inc., GlaxoSmithKline plc. (GSK), Steady Med Ltd., Gilead Sciences Inc., Pfizer Inc., Teva Pharmaceuticals Inc., Actelion Pharmaceuticals Ltd. and Novartis International AG.
Get a customized scope to match your need, ask an expert : https://www.globalinsightservices.com/request-customization/GIS21396
Reasons to buy Pulmonary Arterial Hypertension Market Report:
• Develop comprehensive understanding of market landscape – industry structure, value-chain, key players, trends, drivers, and challenges
• Drive revenue and market-entry strategy by gaining insights into which segments and geographies are largest and likely to grow fastest
• Formulate sales and marketing strategies by gaining understanding of competitors, their positioning, and strengths & weaknesses
• Develop business and M&A strategies through understanding of latest trends and emerging players in the market
• Refine your business plans by understanding impact of disruptions such as Covid-19 and Russia-Ukraine conflict on the market
New Report Published by Global Insight Services : https://www.globalinsightservices.com/reports/hydrogen-projects-database/
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/